<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: materially", fill: "#1c39bb"},
{source: "2: materially", target: "2: adversely", fill: "#1c39bb"},
{source: "2: adversely", target: "2: market value", fill: "#1c39bb"},
{source: "2: market value", target: "2: common stock", fill: "#1c39bb"},
{source: "2: materially", target: "4: operations depend", fill: "#ec3b83"},
{source: "4: operations depend", target: "4: significant extent", fill: "#ec3b83"},
{source: "4: significant extent", target: "4: successfully commercialize new products", fill: "#ec3b83"},
{source: "4: operations depend", target: "5: numerous difficulties", fill: "#986960"},
{source: "5: numerous difficulties", target: "5: commercializing", fill: "#986960"},
{source: "5: commercializing", target: "5: manufacturing products", fill: "#986960"},
{source: "5: manufacturing products", target: "5: compliance with regulatory", fill: "#986960"},
{source: "5: compliance with regulatory", target: "5: requisite regulatory approvals", fill: "#986960"},
{source: "5: requisite regulatory approvals", target: "5: such products", fill: "#986960"},
{source: "5: such products", target: "5: availability", fill: "#986960"},
{source: "5: availability", target: "5: raw materials at", fill: "#986960"},
{source: "5: raw materials at", target: "5: competitive cost", fill: "#986960"},
{source: "5: competitive cost", target: "5: pharmaceutical ingredients", fill: "#986960"},
{source: "5: pharmaceutical ingredients", target: "5: key ingredients", fill: "#986960"},
{source: "5: key ingredients", target: "5: development", fill: "#986960"},
{source: "5: development", target: "5: consuming costly", fill: "#986960"},
{source: "5: consuming costly", target: "5: various factors", fill: "#986960"},
{source: "5: various factors", target: "5: litigation brought by", fill: "#986960"},
{source: "5: litigation brought by", target: "5: competitors", fill: "#986960"},
{source: "5: competitors", target: "5: commercialization", fill: "#986960"},
{source: "5: commercialization", target: "5: profit may fluctuate from period", fill: "#986960"},
{source: "5: profit may fluctuate from period", target: "5: period depending upon", fill: "#986960"},
{source: "5: period depending upon", target: "5: product sales mix", fill: "#986960"},
{source: "5: product sales mix", target: "5: product pricing customer", fill: "#986960"},
{source: "5: product pricing customer", target: "5: active ingredients", fill: "#986960"},
{source: "5: numerous difficulties", target: "6: specific issues", fill: "#cd5700"},
{source: "6: specific issues", target: "6: fluctuation could", fill: "#cd5700"},
{source: "6: fluctuation could", target: "6: new product introductions", fill: "#cd5700"},
{source: "6: new product introductions", target: "6: competition", fill: "#cd5700"},
{source: "6: competition", target: "6: associated pricing pressure", fill: "#cd5700"},
{source: "6: associated pricing pressure", target: "6: certain products", fill: "#cd5700"},
{source: "6: certain products", target: "6: availability", fill: "#cd5700"},
{source: "6: availability", target: "6: raw materials", fill: "#cd5700"},
{source: "6: raw materials", target: "6: profitability", fill: "#cd5700"},
{source: "6: profitability", target: "6: product sales", fill: "#cd5700"},
{source: "6: product sales", target: "6: also dependent upon", fill: "#cd5700"},
{source: "6: also dependent upon", target: "6: excipients", fill: "#cd5700"},
{source: "6: excipients", target: "6: purchased from third parties", fill: "#cd5700"},
{source: "6: purchased from third parties", target: "6: manufacture", fill: "#cd5700"},
{source: "6: manufacture", target: "6: cost effective manner", fill: "#cd5700"},
{source: "6: specific issues", target: "7: unaffiliated third party may", fill: "#555"},
{source: "7: unaffiliated third party may", target: "7: royalties which could", fill: "#555"},
{source: "7: royalties which could", target: "7: operations", fill: "#555"},
{source: "7: unaffiliated third party may", target: "16: pharmaceutical companies", fill: "#0072bb"},
{source: "16: pharmaceutical companies", target: "16: generics through litigation legislature", fill: "#0072bb"},
{source: "16: generics through litigation legislature", target: "16: regulatory efforts", fill: "#0072bb"},
{source: "16: regulatory efforts", target: "16: generic products may suffer", fill: "#0072bb"},
{source: "16: pharmaceutical companies", target: "18: pursuing new patents", fill: "#daa520"},
{source: "18: pursuing new patents", target: "18: existing products which may", fill: "#daa520"},
{source: "18: existing products which may", target: "18: granted just", fill: "#daa520"},
{source: "18: granted just", target: "18: one patent which could extend patent protection", fill: "#daa520"},
{source: "18: one patent which could extend patent protection", target: "18: additional years", fill: "#daa520"},
{source: "18: additional years", target: "18: otherwise delay", fill: "#daa520"},
{source: "18: otherwise delay", target: "18: generic product", fill: "#daa520"},
{source: "18: generic product", target: "18: U S Pharmacopoeia ", fill: "#daa520"},
{source: "18: U S Pharmacopoeia ", target: "18: organization", fill: "#daa520"},
{source: "18: organization", target: "18: publishes industry wide compendia", fill: "#daa520"},
{source: "18: publishes industry wide compendia", target: "18: drug standards", fill: "#daa520"},
{source: "18: drug standards", target: "18: Citizens Petition ", fill: "#daa520"},
{source: "18: Citizens Petition ", target: "18: request amendments", fill: "#daa520"},
{source: "18: request amendments", target: "18: attaching patent extension amendments", fill: "#daa520"},
{source: "18: attaching patent extension amendments", target: "18: enact legislation", fill: "#daa520"},
{source: "18: enact legislation", target: "18: substitution", fill: "#daa520"},
{source: "18: pursuing new patents", target: "25: determination", fill: "#922724"},
{source: "25: determination", target: "25: administrative proceeding could", fill: "#922724"},
{source: "25: administrative proceeding could", target: "25: manufacturing", fill: "#922724"},
{source: "25: manufacturing", target: "25: products which could", fill: "#922724"},
{source: "25: products which could", target: "25: negatively affect", fill: "#922724"},
{source: "25: negatively affect", target: "25: financial condition", fill: "#922724"},
{source: "25: financial condition", target: "25: operations", fill: "#922724"},
{source: "25: determination", target: "28: competitor", fill: "#367588"},
{source: "28: competitor", target: "28: significantly", fill: "#367588"},
{source: "28: significantly", target: "28: competing products", fill: "#367588"},
{source: "28: competitor", target: "29: significant", fill: "#bcd4e6"},
{source: "29: significant", target: "29: inventories", fill: "#bcd4e6"},
{source: "29: significant", target: "37: pharmaceutical companies", fill: "#fc89ac"},
{source: "37: pharmaceutical companies", target: "37: complex costly", fill: "#fc89ac"},
{source: "37: complex costly", target: "37: regulations", fill: "#fc89ac"},
{source: "37: regulations", target: "37: evolve as set forth by", fill: "#fc89ac"},
{source: "37: evolve as set forth by", target: "37: federal government", fill: "#fc89ac"},
{source: "37: federal government", target: "37: government", fill: "#fc89ac"},
{source: "37: government", target: "37: principally", fill: "#fc89ac"},
{source: "37: principally", target: "37: lesser extent by", fill: "#fc89ac"},
{source: "37: pharmaceutical companies", target: "START_HERE", fill: "#fc89ac"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_public_corporations_by_market_capitalization">List of public corporations by market capitalization</a></td>
      <td>The following is a list of publicly traded companies having the greatest market capitalization. In media they are described as being the most valuable companies, a reference to their market value.Market capitalization is calculated from the share price (as recorded on selected day) multiplied by the number of outstanding shares.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Value_(economics)">Value (economics)</a></td>
      <td>In economics, economic value is a measure of the benefit provided by a good or service to an economic agent. It is generally measured relative to units of currency, and the interpretation is therefore "what is the maximum amount of money a specific actor is willing and able to pay for the good or service"?</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mark-to-market_accounting">Mark-to-market accounting</a></td>
      <td>Mark-to-market (MTM or M2M) or fair value accounting refers to accounting for the "fair value" of an asset or liability based on the current market price, or the price for similar assets and liabilities, or based on another objectively assessed "fair" value.  Fair value accounting has been a part of Generally Accepted Accounting Principles (GAAP) in the United States since the early 1990s, and is now regarded as the "gold standard" in some circles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitalization-weighted_index">Capitalization-weighted index</a></td>
      <td>A capitalization-weighted (or cap-weighted) index, also called a market-value-weighted index is a stock market index whose components are weighted according to the total market value of their outstanding shares.  Every day an individual stock's price changes and thereby changes a stock index's value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Generic_trademark">Generic trademark</a></td>
      <td>A generic trademark, also known as a genericized trademark or proprietary eponym, is a trademark or brand name that, because of its popularity or significance, has become the generic term for, or synonymous with, a general class of products or services, usually against the intentions of the trademark's owner.\nA trademark is said to become genericized—or, informally, to have suffered genericide—when it begins as a distinctive product identifier but changes in meaning to become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trademark">Trademark</a></td>
      <td>A trademark (also written trade mark or trade-mark) is a type of intellectual property consisting of a recognizable sign, design, or expression that identifies products or services from a particular source and distinguishes them from others. The trademark owner can be an individual, business organization, or any legal entity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vehicle_emission_standard">Vehicle emission standard</a></td>
      <td>Emission standards  are the legal requirements governing air pollutants released into the atmosphere. Emission standards set quantitative limits on the permissible amount of specific air pollutants that may be released from specific sources over specific timeframes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CARACO PHARMACEUTICAL LABORATORIES LTD      Item 1A Risk Factors:        Risks Related to Our Business                 The following discussion <font color="blue">highlights</font> some of the risks related to     our business and others are <font color="blue">discussed elsewhere</font> in this report</td>
    </tr>
    <tr>
      <td>These and     other risks could <font color="blue">materially</font> and <font color="blue">adversely</font> affect our business, financial     condition, operating results or <font color="blue">cash flows</font> and the <font color="blue">market value</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font> develop or <font color="blue">commercialize <font color="blue">new products</font></font>, our     operating results will suffer</td>
    </tr>
    <tr>
      <td>Our future results of <font color="blue"><font color="blue">operations</font> depend</font> to a <font color="blue"><font color="blue">significant</font> extent</font>     upon our ability to <font color="blue">successfully</font> <font color="blue">commercialize <font color="blue">new products</font></font> in a timely     manner</td>
    </tr>
    <tr>
      <td>There are <font color="blue">numerous difficulties</font> in developing and <font color="blue">commercializing</font>     <font color="blue">new products</font>, including:                                             •       developing, testing and <font color="blue"><font color="blue">manufacturing</font> products</font> in <font color="blue"><font color="blue">compliance with</font> <font color="blue">regulatory</font></font>     standards in a timely fashion;                                             •       receiving the <font color="blue">requisite <font color="blue">regulatory</font> approvals</font> for <font color="blue">such products</font> in a timely     manner;                                             •       the <font color="blue">availability</font> of <font color="blue"><font color="blue">raw materials</font> at</font> a <font color="blue">competitive cost</font>, including active     <font color="blue">pharmaceutical ingredients</font> and other <font color="blue">key ingredients</font>;                                             •       <font color="blue">development</font> and <font color="blue">commercializing</font> a <font color="blue">new products</font> is time consuming, costly and     subject to <font color="blue">various factors</font>, including <font color="blue"><font color="blue">litigation</font> brought by</font> our <font color="blue"><font color="blue">competitor</font>s</font>,     that may delay or prevent the <font color="blue">development</font> and <font color="blue">commercialization</font> of new     products expected to market;       Our gross <font color="blue">profit may fluctuate from period</font> to <font color="blue">period depending upon</font> our     <font color="blue"><font color="blue">product sales</font> mix</font> including new launches, our product pricing, customer     class of trade, and our costs for <font color="blue">active ingredients</font></td>
    </tr>
    <tr>
      <td>Some <font color="blue">specific issues</font> that could result in a <font color="blue">fluctuation could</font>     include any or all of the following;                                             •       the amount of <font color="blue">new product introductions</font>;                                         10     ______________________________________________________________________                                             •       the level of <font color="blue">competition</font> and <font color="blue">associated pricing pressure</font> in the marketplace     for <font color="blue">certain products</font>;                                             •       the <font color="blue">availability</font> of <font color="blue">raw materials</font>;            The <font color="blue">profitability</font> of our <font color="blue">product sales</font> is <font color="blue">also <font color="blue">dependent upon</font></font> the     prices we are able to charge for all our products, the costs of <font color="blue">excipients</font>     <font color="blue">purchased from <font color="blue">third parties</font></font>, and our ability to <font color="blue">manufacture</font> our products in     a <font color="blue">cost effective manner</font></td>
    </tr>
    <tr>
      <td>An <font color="blue"><font color="blue">unaffiliated</font> third party may</font> make a claim for <font color="blue">royalties which could</font> have     a material adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In 1993, we <font color="blue">entered into</font> a <font color="blue">products <font color="blue">agreement</font> with</font> an <font color="blue">unaffiliated</font>     generic  drug  company (the “Non-Affiliate”)</td>
    </tr>
    <tr>
      <td>Under the <font color="blue">agreement</font>, two     products were to be delivered to us in exchange for royalties and options</td>
    </tr>
    <tr>
      <td>Pursuant to the <font color="blue">agreement</font>, we received a <font color="blue">formulation</font> for one product (“the     Product”) from the Non-Affiliate</td>
    </tr>
    <tr>
      <td>However, we have determined that the     <font color="blue">formula provided</font> to us by the Non-Affiliate <font color="blue">with respect</font> to the Product is     <font color="blue">different</font>  than  the  <font color="blue">formula approved by</font> the FDA and <font color="blue">manufacture</font>d and     introduced by us</td>
    </tr>
    <tr>
      <td>Accordingly, since April 2003, we have <font color="blue">discontinued</font> to     <font color="blue">accrue royalties</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Product </font>has been one of our <font color="blue">top selling products</font></td>
    </tr>
    <tr>
      <td>There  is  no  assurance that the Non-Affiliate will not challenge our     <font color="blue">determination</font> and make a claim that royalties and/or options are owed</td>
    </tr>
    <tr>
      <td>If     successful, such a claim could have a material adverse effect on our results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If brand <font color="blue">pharmaceutical companies</font> are successful in limiting the use of     generics through <font color="blue">litigation</font>, legislature and <font color="blue"><font color="blue">regulatory</font> efforts</font>, our sales     of <font color="blue"><font color="blue">generic product</font>s may suffer</font></td>
    </tr>
    <tr>
      <td>Many brand <font color="blue">pharmaceutical companies</font> increasingly have used state     and <font color="blue">federal legislative</font> and <font color="blue">regulatory</font> and other <font color="blue"><font color="blue">litigation</font> as</font> means to     delay generic <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>These efforts have included:                                             •       <font color="blue">pursuing new patents</font> for <font color="blue">existing products which may</font> be <font color="blue">granted just</font> before     the expiration of one patent, which could extend patent protection for     <font color="blue">additional years</font> or <font color="blue">otherwise delay</font> the launch of our <font color="blue">generic product</font>;                                             •       submitting for changes in <font color="blue">U S Pharmacopoeia </font>which is an <font color="blue">organization</font> that     <font color="blue">publishes industry wide compendia</font> of <font color="blue">drug standards</font>;                                             •       using the Citizen’s Petition process to <font color="blue">request amendments</font> to FDA standards;                                             •       <font color="blue">attaching patent extension amendments</font> to non-related federal legislation;                                             •       engage in state-by-state initiative to <font color="blue">enact legislation</font> that restricts     <font color="blue">substitution</font> of certain generic drugs which could possibly impact products     that we are developing</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we infringe their <font color="blue">proprietary rights</font> and may     <font color="blue">prevent us from <font color="blue">manufacturing</font></font> and selling some of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>, use and sale of <font color="blue">new products</font> that are the subject     of <font color="blue">conflicting patent rights</font> have been the subject of substantial <font color="blue">litigation</font>     in the <font color="blue">pharmaceutical industry</font></td>
    </tr>
    <tr>
      <td>These lawsuits relate to the validity and     <font color="blue">infringement</font> of patents or <font color="blue">proprietary rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may have     to <font color="blue">defend against charges</font> that we <font color="blue">violated patents</font> or <font color="blue">proprietary rights</font> of     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be costly and time-consuming, and <font color="blue">could divert</font>     the attention of our <font color="blue">management</font> and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>If it is found that     we <font color="blue">infringe on</font> the rights of others, we could lose our right to develop or     <font color="blue">manufacture</font>  products  or could be required to <font color="blue">pay monetary damages</font> or     royalties to license <font color="blue">proprietary rights</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>As a result, an     adverse <font color="blue">determination</font> in a judicial or <font color="blue">administrative proceeding could</font>     prevent  us  from  <font color="blue">manufacturing</font> and selling a product(s), which could     <font color="blue"><font color="blue">negatively</font> affect</font> our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our policies regarding returns and <font color="blue">chargebacks</font> by wholesalers may reduce our     revenues in <font color="blue">future fiscal periods</font></td>
    </tr>
    <tr>
      <td>Based  on  industry  practice, <font color="blue">generic product</font> <font color="blue">manufacture</font>rs     including Caraco have <font color="blue">liberal return policies</font> and make <font color="blue">decisions whether</font> or     not to <font color="blue">provide shelf stock allowances</font> (or credits) for <font color="blue"><font color="blue">inventories</font> on hand</font>     on product that has <font color="blue">already been sold</font> to the customer</td>
    </tr>
    <tr>
      <td>If a new <font color="blue">competitor</font>     enters the marketplace and <font color="blue"><font color="blue">significant</font>ly</font> lowers the price of any of its     <font color="blue">competing products</font>, it is possible that we would make a decision to reduce     the price of our product</td>
    </tr>
    <tr>
      <td>As a result, we would be obligated to provide     <font color="blue">significant</font> credits to our customers who are then holding <font color="blue">inventories</font> of     <font color="blue">such products</font>, which could reduce sales revenue and gross margin for the     period the credit is provided</td>
    </tr>
    <tr>
      <td>Like our <font color="blue"><font color="blue">competitor</font>s</font>, we also give credits     for <font color="blue">chargebacks</font> to <font color="blue"><font color="blue">wholesale customer</font>s</font> that have <font color="blue">contracts with us</font> for their     sales to <font color="blue">chain drug retail</font>, group purchasing <font color="blue">organization</font>s, or other retail     customers</td>
    </tr>
    <tr>
      <td>A <font color="blue">chargeback represents</font> an <font color="blue">amount payable</font> in the future to a     wholesaler for the                                         11     ______________________________________________________________________       <font color="blue">difference between</font> the <font color="blue">invoice price paid</font> to us by our <font color="blue">wholesale customer</font>     for  a  particular  product and the <font color="blue">negotiated contract price</font> that the     wholesaler’s customer pays for that product</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">establish reserves</font>     <font color="blue">based on</font> our historical experience and our best estimates of the potential     impact that these <font color="blue">policies may</font> have, we <font color="blue">cannot ensure</font> that our reserves are     adequate or that actual product returns, allowances and <font color="blue">chargebacks</font> will not     exceed our estimates, which could <font color="blue">adversely</font> affect our <font color="blue">financial condition</font>,     <font color="blue">cash flows</font> and <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue"><font color="blue">key personnel</font> could</font> cause our business to suffer</td>
    </tr>
    <tr>
      <td>The success of our present and future <font color="blue">operations</font> will depend, to a     <font color="blue"><font color="blue">significant</font> extent</font>, upon the experience, <font color="blue">abilities</font> and <font color="blue">continued services</font> of     <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to attract and     retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Extensive  </font>industry  regulation  has had, and <font color="blue">will continue</font> to have, a     <font color="blue">significant</font> impact on our business, <font color="blue">especially</font> our product <font color="blue">development</font>,     <font color="blue">manufacturing</font> and <font color="blue">distribution</font> cap<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>All <font color="blue">pharmaceutical companies</font>, are subject to complex, costly     <font color="blue">regulations</font> that continue to <font color="blue">evolve as set forth by</font> the <font color="blue">federal <font color="blue">government</font></font>,     <font color="blue">principally</font> the FDA and to a <font color="blue">lesser extent by</font> the DEA and state <font color="blue">government</font>     agencies</td>
    </tr>
    <tr>
      <td>The Federal Food, Drug and Cosmetic Act, the Controlled Substances     Act  and  other  federal  statutes and <font color="blue">regulations</font> govern the testing,     <font color="blue">manufacturing</font>, storage, packing, labeling, record keeping, safety, sales and     marketing, promotion, and <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>Under  these <font color="blue">regulations</font>, we are subject to <font color="blue">periodic routine</font>     inspection of our facilities, procedures, <font color="blue">operations</font> and the testing of our     products  by  the FDA, the DEA and other <font color="blue">authorities</font> that regulate our     business</td>
    </tr>
    <tr>
      <td>These  <font color="blue">inspections</font>  are  designed to confirm that we are in     <font color="blue">compliance with</font> all applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>an inspection, the FDA     may issue notices on Form 483 and /or <font color="blue"><font color="blue">warning letter</font>s</font> that could cause us to     <font color="blue">modify certain activities</font> identified during the inspection</td>
    </tr>
    <tr>
      <td>A Form 483     notice is <font color="blue">generally issued at</font> the <font color="blue">conclusion</font> of a FDA inspection and lists     <font color="blue">conditions</font>  the  FDA  <font color="blue">inspectors</font> believe <font color="blue">may violate cGMP</font> or other FDA     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>FDA <font color="blue">guidelines specify</font> that a <font color="blue">warning letter</font> is <font color="blue">issued only</font> for     violations of “<font color="blue">regulatory</font> significance” for which the failure to promptly     and  <font color="blue">adequately</font>  achieve  <font color="blue">correction</font>  may  be expected to result in an     <font color="blue">enforcement action</font></td>
    </tr>
    <tr>
      <td>Possible <font color="blue">sanctions could</font> include <font color="blue">among others</font>, FDA     issuance of adverse publicity, fines, product recalls, total or partial     suspension of production and/or <font color="blue">distribution</font>, suspension of the FDA’s review     of product applications, <font color="blue">enforcement action</font>s, injunctions, and civil or     <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>These sanctions, if imposed, could <font color="blue">materially</font> harm our     operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain circumstances</font>, the     FDA also has the authority to <font color="blue">revoke previously granted drug approvals</font></td>
    </tr>
    <tr>
      <td>Although we have internal compliance programs in place these <font color="blue">programs may</font>     not meet <font color="blue">regulatory</font> agency standards or if compliance is deemed deficient in     any <font color="blue">significant</font> way, it could <font color="blue">materially</font> harm our business</td>
    </tr>
    <tr>
      <td>Certain of our     vendors that sell to us are also subject to similar regulation and periodic     <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>Sales  of  our  products  may continue to be <font color="blue">adversely</font> affected by the     continuing <font color="blue">consolidation</font> of the <font color="blue">distribution</font> network and the <font color="blue">concentration</font>     of customers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal customers</font> are wholesale drug <font color="blue">distributors</font>, major     retail  <font color="blue">drug store chains</font> and <font color="blue">managed care</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">customers comprise</font> a     <font color="blue">significant</font> part of the <font color="blue">distribution</font> network for <font color="blue">pharmaceutical products</font> in     the US This <font color="blue">distribution</font> network is continuing to undergo <font color="blue">significant</font>     <font color="blue">consolidation</font>  marked  by  mergers  and  <font color="blue">acquisitions</font>  <font color="blue">among wholesale</font>     <font color="blue">distributors</font> and the growth of large retail <font color="blue">drug store chains</font> and managed     <font color="blue">care companies</font></td>
    </tr>
    <tr>
      <td>As a result, a small number of large wholesale <font color="blue">distributors</font>     and large chain drug stores and <font color="blue">managed care</font> providers control a <font color="blue">significant</font>     share of the market</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">consolidation</font> of <font color="blue">drug wholesalers</font>,     retailers  and  <font color="blue">managed care</font> providers will increase pricing and other     competitive pressures on drug <font color="blue">manufacture</font>rs, including Caraco</td>
    </tr>
    <tr>
      <td>Even  if  we  are  able  to  obtain  <font color="blue">regulatory</font>  approvals for our new     <font color="blue">pharmaceutical products</font>, the success of those products is <font color="blue">dependent upon</font>     <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Levels of <font color="blue">market <font color="blue">acceptance</font></font> for our <font color="blue">new products</font> could be     <font color="blue">impacted by</font> several factors, including:                                             •       <font color="blue">availability</font> of alternate product from our <font color="blue"><font color="blue">competitor</font>s</font>;                                             •       the timing of our market entry;                                             •       <font color="blue">acceptance</font> of our product on <font color="blue">government</font> and private <font color="blue">formularies</font>;                                         12     ______________________________________________________________________                                             •       and the prices that we sell our <font color="blue">products at versus</font> our <font color="blue"><font color="blue">competitor</font>s</font>’ prices</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors amongst others</font> are beyond our control and could <font color="blue">materially</font>     have a negative effect on <font color="blue">operations</font> and the <font color="blue">market value</font> of our common     stock</td>
    </tr>
    <tr>
      <td>From time to time a <font color="blue">relatively</font> small group of products could represent a     <font color="blue">significant</font> portion of our sales and if the <font color="blue">products sales</font> of these product     decline  <font color="blue">unexpectedly</font>  it could have a negative material effect on our     business and could cause our <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Sales  of a limited number of our <font color="blue">products often represent</font> a     <font color="blue">significant</font> portion of our <font color="blue">net revenues</font> and <font color="blue">net earnings</font></td>
    </tr>
    <tr>
      <td>If the volume or     pricing  of  our  largest selling products declines in the future, our     business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> could be <font color="blue">materially</font>     <font color="blue">adversely</font> affected, and the <font color="blue">market value</font> of our <font color="blue">common stock</font> could decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may be able to develop products and <font color="blue">processes competitive</font>     with or superior to our own for many reasons, including that they may have:                                             •       <font color="blue">proprietary processes</font> or <font color="blue">product delivery systems</font>;                                             •       <font color="blue">larger research</font> and <font color="blue">development</font> and <font color="blue">marketing staffs</font>;                                             •       <font color="blue">larger production capacity</font> in general or for a <font color="blue">given product</font>;                                             •       more <font color="blue">financial resources than</font> Caraco;                                             •       more experience in developing new drugs;       Our reporting and <font color="blue">payment <font color="blue">obligations</font> under</font> Medicaid and other <font color="blue">government</font>al     programs are complex and may change <font color="blue">periodically based upon new guidelines</font>     provided those agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>the  <font color="blue">regulations</font>  regarding  reporting and payment     <font color="blue">obligations</font>  are  complex,  we  believe we are properly and <font color="blue">accurately</font>     <font color="blue">calculating</font> and reporting the amounts owed in respect <font color="blue">of Medicaid </font>and other     <font color="blue">government</font>al pricing programs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">calculations</font> are subject to review and     <font color="blue">challenge by</font> the applicable <font color="blue">government</font>al agencies, and it is possible that     any <font color="blue">such review could</font> result in material changes</td>
    </tr>
    <tr>
      <td>Any <font color="blue">government</font>al agencies     <font color="blue">may initiate</font> an <font color="blue">investigation</font> of the Company and could impose, <font color="blue">based on</font> a     claim of violation of fraud and false claims laws or otherwise, civil and/or     criminal sanctions, including fines, penalties and possible exclusion from     federal health care programs (including <font color="blue">Medicaid and Medicare</font>)</td>
    </tr>
    <tr>
      <td>Sun Global could determine not to <font color="blue">assist us</font> in our research and <font color="blue">development</font>     and Sun Pharma <font color="blue">could cease supplying support</font> and <font color="blue">raw materials</font>                 <font color="blue">Collectively Sun Global and Sun Pharma </font>could determine that its     own  research  and  <font color="blue">development</font>  takes <font color="blue">precedent over</font> the research and     <font color="blue">development</font> it provides to Caraco</td>
    </tr>
    <tr>
      <td>This could cause a gap in our research     and <font color="blue">development</font> timelines until Caraco <font color="blue">could increase</font> its own cap<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">gap could possibly</font> cause <font color="blue">future growth concerns until resolved</font></td>
    </tr>
    <tr>
      <td>Sun     Pharma <font color="blue">which supplies us raw</font> material <font color="blue">could face supply issues</font> or not be     capable of supplying the raw material for <font color="blue">certain products</font> we <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>This could cause <font color="blue">lower sales</font> or <font color="blue">possibly lower margins until</font> we negotiate     <font color="blue">new suppliers</font> and gain the <font color="blue">requisite approvals</font> to <font color="blue">manufacture</font> our product     with a new raw material source</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our net sales are from the sales of a limited     number of customers</td>
    </tr>
    <tr>
      <td>Should we lose a <font color="blue">particular contract with</font> a customer or     the  customer is acquired by a non-customer, our sales and operational     results could face a <font color="blue">significant</font> decline</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our <font color="blue">net revenues</font> are <font color="blue">derived from sales</font>     to  a  limited number of customers</td>
    </tr>
    <tr>
      <td>As such, a reduction in or loss of     business <font color="blue">with <font color="blue">one customer</font></font>, or if <font color="blue">one customer</font> were to experience <font color="blue">difficulty</font>     in <font color="blue">paying us on</font> a <font color="blue">timely basis</font>, our business, <font color="blue">financial position</font> and results     of <font color="blue">operations</font> could be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our  product  <font color="blue">liability</font>  insurance  may not be enough to <font color="blue">mitigate risk</font>     <font color="blue">associated with</font> our products                                         13     ______________________________________________________________________                 Though we believe we carry adequate product <font color="blue">liability</font> insurance it     is possible that a lawsuit or <font color="blue">lawsuits could exceed</font> our <font color="blue">insurance levels</font> and     have a <font color="blue">negative impact on</font> our financial results       We  <font color="blue">manufacture</font>  our  <font color="blue">product line predominately from one</font> FDA approved     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>There is a <font color="blue">possibility</font> that our <font color="blue">production could</font> be <font color="blue">negatively</font>     <font color="blue">impacted by</font> a closure of this <font color="blue">facility</font>                  Should our <font color="blue">facility</font> located in Detroit incur a closure of any type     it would have a <font color="blue">negative impact on</font> our results</td>
    </tr>
    <tr>
      <td>We carry a limited amount of     finished goods on hand and much of our inventory is either work in progress     or is in <font color="blue">bulk amounts</font></td>
    </tr>
    <tr>
      <td>Should we experience an act of God that closes our     <font color="blue">facility</font>,  or production is stopped or a <font color="blue">power outage continues</font> for an     <font color="blue">inordinate period</font> of time, it could have a <font color="blue">significant</font> negative effect on     our results</td>
    </tr>
    <tr>
      <td>Any of these factors and others could have a material adverse     effect on our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> and     could cause the <font color="blue">market value</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
  </tbody>
</table>